EEVIA HEALTH REOPENS INGREDIENT FACTORY AFTER INVESTMENTS

Eevia Health Oy, a Finnish producer of health ingredients made from organically-certified plant extracts, has upgraded its green-chemistry manufacturing plant in Finland to meet strong demand from customers.

During the first four months of 2020, Eevia Health invested in new equipment, machines, and technology to improve functionality, productivity, and throughput of the special-purpose ingredient factory. The equipment-upgrade amount to an investment of approximately 1 million euros and is 100% equity-financed by Eevia Health owners. It includes significant improvement in functionality, directed at maintaining high quality in the extraction process of complex compounds from natural plant material. Located near the harvest areas of its raw materials, Eevia Health offers the shortest value chain in the industry, a strong focus on sustainability and traceability and products with an environmentally friendly carbon footprint.

"We are very pleased to have completed this factory-upgrade. It puts us as a competitive company for high quality, branded ingredients in a 500 billion euro global nutraceutical ingredients market. The investments will especially benefit our manufacturing of polyphenolic extracts from arctic bilberries and lingonberries, as well as elderberries. Some of the improvements are radical. For instance, earlier, the residence time (the time the extracted liquid has to be in the process step) for extraction liquids in one process step was four hours, whiles now this step only takes a few seconds. This greatly benefits quality.", says CEO and Founder Stein Ulve from Eevia Health Oy.

Eevia Health Oy will celebrate the reopening of its modern green-chemistry production facility in Kauhajoki, with a formal opening ceremony as a live-streamed webinar at the end of June.

Eevia Health Oy

Eevia Health Oy, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests above the Arctic Circle. The focus is on products that protect human health prophylactically, meaning they work to reduce the risk of developing a disease. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- and TNF- cell signaling molecules, which are very important in the immune response to pathogens (virus, etc.). Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the Retina, which may reduce the risk of developing the eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. All raw materials, such as lingonberry, bilberry, Chaga-mushroom, and pine bark, are grown in the wild and hand-picked in a sustainable fashion. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw material forest source in Finnish Lapland. All the ingredients are organically certified. The short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency.

The green-chemistry extraction and enrichment technologies Eevia Health Oy operate, allow for safe and effective ingredients of high quality, for dietary supplements and other applications. Eevia Health value proposition offers safe and effective products made with responsible practices, transparency, and authenticity. The ingredients, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts, are sold globally as ingredients to dietary supplement and food applications.

Seinäjoki, Finland, June 1st, 2020

For additional information, please contact:
Stein Ulve, CEO
Eevia Health Oy
Mobile: +358 400 22 5967
Email: [email protected]

Fred Ramberg, Chairman of the Board
Eevia Health Oy
Mobile: +358 500 46 0944
Email: [email protected]

Positive results from human clinical study concluded on Feno-Chaga® Organic

Eevia Health Plc (" Eevia" or" The Company") has concluded a human clinical study of the effects of Eevia's branded ingredient Feno-Chaga® Organic on Upper-Respiratory Tract Infections (URTIs) and Psychological Mood State with positive and promising results.


Eevia Health Plc Interim Report Quarter 3 - 2021

The Board and CEO of Eevia Health Plc now present the Interim Report for the third quarter of 2021, covering the period 1 July through 30 September 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com


Notice to the Extraordinary General Meeting of Eevia Health Abp

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.


Correction: Eevia Health's Board of Directors has resolved, subject to approval at an Extraordinary General Meeting, on a directed share issue of SEK 20 million

This is a correction to press release published 10 November, 2021 where the press release lacked a reference to the EU's Market Abuse Regulation (MAR).

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.


Eevia Health's Board of Directors has resolved, subject to approval at an Extraordinary General Meeting, on a directed share issue of SEK 20 million

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.


Eevia Health Plc received new sales orders for organic pine bark extract

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from a leading organic supplement brand for supply of the Fenoprolic® 70 Organic (organic pine bark extract). The sales value of this start order is c.65,000 EUR, but the customer has a strong record on new product launches, and it is therefore expected to create repeat sales of this product going forward.  


Eevia Health Plc - Interim Report Quarter 2 - 2021

The Board and CEO of Eevia Health Plc hereby present the Interim Report for the second quarter 2021, covering the period April 1st through June 30th, 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com 


Eevia Health Plc completed first phase of a planned capacity increase and plant improvement

Eevia Health Plc, ("Eevia" or "The Company"), has installed new capacities and automation equipment for processing and evaporation of natural plant extract liquids. As of August 1st, the newly installed machines and technologies are working satisfactorily, with improved yield, productivity, and cost efficiency. These investments support the company's strong growth and strategic positioning, as communicated in the May 2021 information memorandum.


Eevia Health receives new sales orders for organic bilberry extract with a contract value of approx. SEK 3 million

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from Ingredient Plus of Australia for supply of bilberry extract with minimum 36% anthocyanins. The sales value of these orders is c. SEK 3 million, which to be prepaid and delivered in Q3-21.



Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted